Nyxoah Announces Issuance of First Tranche of Convertible Bonds
Mont–Saint–Guibert, Belgium – December 19, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext [...] Read more »
Nyxoah Annonce L’Émission de la Première Tranche des Obligations Convertibles
Nyxoah Annonce L’Émission de la Première Tranche des Obligations Convertibles
Mont–Saint–Guibert, Belgique – 19 décembre 2025, [...] Read more »
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands
First Genio implants successfully performed at OLVG West and Zuyderland hospitals
Read more »
Nyxoah Annonce le Lancement Commercial de la Thérapie Innovante Genio® Aux Pays-Bas
Nyxoah Annonce le Lancement Commercial de la Thérapie Innovante Genio® Aux Pays–Bas
Premières implantations Genio réalisées avec succès dans les hôpitaux [...] Read more »
Zoom launches AI Companion 3.0 with agentic workflows, transforming conversations into action
- Zoom’s new AI Companion web surface leverages work conversations to help save time and boost productivity
- Personal workflows (beta), AI Companion 3.0 features for Zoom Docs (coming soon), and [...] Read more »
Namib Minerals – Operational Update
NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) — Namib Minerals Ltd. (“Namib” or the “Company”) today provided an operational update highlighting improving stability and cost performance across its [...] Read more »
Datavault AI Announces Hockey Hall of Famer Jeremy Roenick Joins to Monetize Sports Data and Lead Pioneering International NIL Exchange
PHILADELPHIA, Dec. 15, 2025 (GLOBE NEWSWIRE) — Datavault AI Inc. (NASDAQ: DVLT; the “Company” or “Datavault AI”), a leading provider of patented agentic AI platforms for data observation, valuation and [...] Read more »
Zoom Leads A Workplace Revolution
SAN JOSE, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) — Today, on behalf of employees everywhere, Zoom announced the launch of a major brand campaign developed with Colin Jost’s No Notes Productions lampooning the [...] Read more »
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
- REC–4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)
- After 12 weeks [...] Read more »